bioRxiv Science⌕ Search

Biology subjects

Pitkänen, E.

Publications and source records attributed to Pitkänen, E..

5 recordsLinked to original sources

Towards a foundation model for raw nanopore signal through discrete tokenization

Nanopore sequencing reads nucleic acids as changes in ionic current that carry information beyond the base sequence. Self-supervised pretrained models have advanced genomic sequence modeling and single-cell analysis, but remain underexplored for raw nanopore signals, which are continuous and lack a native token vocabulary. Here we present Brieno, an approach combining reconstruction-based tokenization through residual vector quantization with a Transformer for contextual representation learning. We pretrain the Transformer using masked-token prediction on raw nanopore signals from 118 million reads. With frozen or fine-tuned features, the model identifies species without requiring reference genomes. It complements Dorado by accurately classifying reads left unclassified in native-barcode demultiplexing, approaches Dorado's basecalling performance across six genomes, and exceeds Dorado's specialized 5-methylcytosine model as well as a dedicated 6-methyladenine caller. Brieno also supports accurate CpG methylation detection with limited labeled data. Across tasks, pretrained contextual representations improve downstream performance over non-pretrained baselines and generalize across sequencing runs. Together, these findings support self-supervised pretraining as a basis for transferable representations of raw nanopore signals.

bioinformatics↗

muat: portable transformer-based method for tumour classification and representation learning from somatic variants

MotivationDeep neural networks have proven effective in classifying tumour types using next-generation sequencing data. However, developing transferable models that work across heterogeneous operating environments remains challenging due to differences in cohort compositions and data generation protocols, privacy concerns, and limited computational capabilities. ResultsWe introduce muat, a transformer-based software for tumour classification using somatic variant data from whole-genome (WGS) and whole-exome sequencing (WES). Building on previously developed MuAt and MuAt2 models, we distribute the software via Docker containers and Bioconda for deployment in high-performance computing (HPC) systems and Secure Processing Environments (SPEs). Using a downloadable MuAt checkpoint, we reproduce the performance reported in the original study on whole genome (PCAWG; 89% accuracy in histological tumour typing) and exome sequencing data (TCGA; 64% accuracy). Cross-cohort evaluation in Genomics England SPE achieved 81% accuracy without retraining and 89% following fine-tuning. As a demonstration of the softwares adaptability, we also deployed muat within the iCAN Digital Precision Cancer Medicine Flagships SPE and integrated it into a Nextflow-managed workflow. Availability and implementationmuat is available through conda (www.anaconda.org/bioconda/muat) and GitHub (https://github.com/primasanjaya/muat), under the Apache 2.0 License. Contactprima.sanjaya@helsinki.fi, esa.pitkanen@helsinki.fi; website: mlbiomed.net

bioinformatics↗

petVAE: A Data-Driven Model for Identifying Amyloid PET Subgroups Across the Alzheimer's Disease Continuum

Amyloid-{beta} (A{beta}) PET imaging is a core biomarker and is sufficient for the biological diagnosis of Alzheimers disease (AD). Here, we aimed to identify biologically meaningful subgroups across the continuum of A{beta} accumulation using a data-driven deep learning approach, without imposing predefined thresholds for A{beta} negativity or positivity. We analyzed 3,110 A{beta} PET scans from the Alzheimers Disease Neuroimaging Initiative and Anti-Amyloid Treatment in Asymptomatic Alzheimers Disease studies to develop petVAE, a two-dimensional variational autoencoder. The model accurately reconstructed scans without prior labeling, selection by scanner or region of interest. Latent representations of scans extracted from petVAE were used to visualize and cluster the AD continuum. Clustering yielded four groups: two predominantly A{beta} negative (A{beta}-, A{beta}-+) and two predominantly A{beta} positive (A{beta}+, A{beta}++). All clusters differed in standardized uptake value ratio (p < 1.64x10-) and cerebrospinal fluid (CSF) A{beta} (p < 0.02), demonstrating petVAEs ability to assign scans along the A{beta} continuum. Extreme clusters (A{beta}-, A{beta}++) resembled conventional A{beta} negative and positive groups and differed in cognition, APOE {varepsilon}4 prevalence, A{beta} and tau CSF biomarkers (p < 3x10-). Intermediate clusters (A{beta}-+, A{beta}+) showed higher odds of carrying at least one APOE {varepsilon}4 allele versus A{beta}- (p < 0.03). Participants in A{beta}+ or A{beta}++ clusters exhibited faster progression to AD (A{beta}+ hazard ratio = 2.42, A{beta}++ HR = 9.43; p < 1.17x10-). Thus, petVAE was capable of reconstructing PET scans while extracting latent features that capture the AD continuum and define biologically meaningful subgroups, enabling data-driven characterization of preclinical disease stages.

bioinformatics↗

Comparative analysis of molecular representations in prediction of cancer drug combination synergy and sensitivity

AO_SCPLOWBSTRACTC_SCPLOWApplication of machine and deep learning methods in drug discovery and cancer research has gained a considerable amount of attention in the past years. As the field grows, it becomes crucial to systematically evaluate the performance of novel computational solutions in relation to established techniques. To this end we compare rule-based and data-driven molecular representations in prediction of drug combination sensitivity and drug synergy scores using standardized results of 14 throughput screening studies, comprising 64 200 unique combinations of 4 153 molecules tested in 112 cancer cell lines. We evaluate the clustering performance of molecular representations and quantify their similarity by adapting the Centered Kernel Alignment metric. Our work demonstrates that to identify an optimal molecular representation type it is necessary to supplement quantitative benchmark results with qualitative considerations, such as model interpretability and robustness, which may vary between and throughout preclinical drug development projects. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=168 SRC="FIGDIR/small/439299v2_ufig1.gif" ALT="Figure 1"> View larger version (41K): org.highwire.dtl.DTLVardef@1bc4509org.highwire.dtl.DTLVardef@1586640org.highwire.dtl.DTLVardef@a11129org.highwire.dtl.DTLVardef@6dc93b_HPS_FORMAT_FIGEXP M_FIG C_FIG

bioinformatics↗

Retrotransposon insertions can initiate colorectal cancer and are associated with poor survival

Genomic instability pathways in colorectal cancer (CRC) have been extensively studied, but the role of retrotransposition in colorectal carcinogenesis remains poorly understood. Although retrotransposons are usually repressed, they become active in several human cancers, in particular those of the gastrointestinal tract. Here we characterize retrotransposon insertions in 202 colorectal tumor whole genomes and investigate their associations with molecular and clinical characteristics. We found highly variable retrotransposon activity among tumors and identified recurrent insertions in 15 known cancer genes. In approximately 1% of the cases we identified insertions in APC, likely to be tumor-initiating events. Insertions were positively associated with the CpG island methylator phenotype and the genomic fraction of allelic imbalance. Clinically, high number of insertions was independently associated with poor disease-specific survival.

genomics↗